用口袋条件扩散模型生成兼具强结合力与良好药学性质的3D新分子。
Generating Developable 3D Molecules via Pocket-Conditioned Diffusion and Property-Aware Optimization

- 基于多尺度口袋表征与扩散模型,实现靶点口袋引导的分子生成。
- 在人体疾病靶点上平均结合能达-8.85 kcal/mol,药学性质提升最高73%。
- 可直接生成可实验验证的候选药物,支持新药重定位与高效筛选。
药物发现耗时且资源密集,推动了基于扩散模型的从头药物设计方法发展。现有基于扩散的结构基药物设计(SBDD)方法通常将口袋与配体表征学习耦合,仅在原子层面建模相互作用,且优先考虑结合亲和力而忽视其他可开发性属性。本文提出conDitar-dev,一种条件扩散式SBDD框架,用于生成具有强结合亲和力和优良ADMET性质的配体。该框架包含三个模块:msPRL(预训练多尺度口袋表征学习模块)、conDitar(由msPRL引导的口袋条件扩散模型)以及paOPT(生成阶段优化配体可开发性的方法)。在新构建的人类疾病靶点基准测试中,conDitar-dev超越现有最优SBDD基线,平均结合得分达-8.85 kcal/mol。在五项ADMET属性上,相比conDitar性能提升最高达73%。为验证其生成可开发分子的能力,我们将其应用于两个已验证的成药靶点:程序性死亡配体1(PD-L1)和集落刺激因子1受体(CSF1R)。通过conDitar-dev生成的分子及其类似物已被实验合成并生物测试。针对PD-L1的两个分子分别获得SPR测得的K_D值为3.49和3.75 μM。基于这些设计分子的命中扩展,发现了选择性CSF1R抑制剂,其IC_{50}低至200 nM,同时揭示了药物重定位机会。
原文摘要 · Abstract (English)
Drug discovery and development is time-consuming and resource-intensive, motivating computational approaches such as diffusion models for de novo drug design. Many such models follow the structure-based drug design (SBDD) paradigm, generating molecules to fit a target binding pocket. However, existing diffusion-based SBDD methods typically couple pocket and ligand representation learning, model interactions only at the atom level, and prioritize binding affinity over other developability properties. Here, we introduce conDitar-dev, a conditional diffusion-based SBDD framework for generating ligands with strong binding affinities and favorable ADMET properties. It consists of three modules: msPRL, a pretrained multi-scale pocket representation learning module; conDitar, a pocket-conditioned diffusion model guided by msPRL representations; and paOPT, a generation-time method for optimizing ligand developability. On a newly curated benchmark of human disease targets, conDitar outperforms state-of-the-art SBDD baselines, achieving an average binding score of -8.85 kcal/mol. Across five ADMET properties, conDitar-dev improves performance by up to 73% over conDitar. To further validate the abilities of conDitar-dev to generate developable molecules, we have applied it to two validated druggable targets: programmed death-ligand 1 (PD-L1) and colony-stimulating factor 1 receptor (CSF1R) proteins. Top-ranked generatively designed molecules and their analogs have been experimentally synthesized and biologically tested. Two molecules generated directly by conDitar-dev for PD-L1 exhibited SPR-derived $K_D$ values of 3.49 and 3.75 $μ$M, respectively. Hit expansion based on conDitar-dev-designed molecules identified selective CSF1R inhibitors with IC$_{50}$ values as low as 200 nM, while also uncovering opportunities for drug repositioning.
Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。